Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06947993 · ClinicalTrials.gov registry record · Phase 2

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

A Phase 2 study of Atopic Dermatitis, sponsored by Novartis Pharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
224
Enrollment target
20
Study locations

NCT06947993 is a Phase 2 study of Atopic Dermatitis that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 224 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06947993, a Phase 2 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
224 participants
Enrollment target
20
Study locations

Study Summary

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

Conditions Studied

Atopic Dermatitis

Interventions

  • DRUG Placebo
  • DRUG GHZ339

Study Locations (20)

California

  • Novartis Investigative Site - Fountain Valley
  • Novartis Investigative Site - Los Angeles
  • Novartis Investigative Site - Sacramento
  • Novartis Investigative Site - Santa Ana
  • Novartis Investigative Site - Santa Monica

Texas

  • Novartis Investigative Site - Arlington
  • Novartis Investigative Site - Cypress
  • Novartis Investigative Site - Dallas

Alabama

  • Novartis Investigative Site - Birmingham
  • Novartis Investigative Site - Birmingham

Georgia

  • Novartis Investigative Site - Atlanta
  • Novartis Investigative Site - Macon

Arkansas

  • Novartis Investigative Site - Fort Smith

District of Columbia

  • Novartis Investigative Site - Washington D.C.

Florida

  • Novartis Investigative Site - Miami

Kentucky

  • Novartis Investigative Site - Louisville

Trial Details

FieldValue
Enrollment Target 224 participants
Start Date 2025-05-16
Est. Completion 2028-12-22
Phase Phase 2

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06947993

The ClinicalTrials.gov registry entry for NCT06947993 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (63% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06947993 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Texas, Alabama.

Frequently Asked Questions

What is clinical trial NCT06947993 about?

NCT06947993 is a clinical study titled "Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis". This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

What is the current status of trial NCT06947993?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 224 participants. The study started on 2025-05-16. Estimated completion is 2028-12-22.

What conditions does trial NCT06947993 study?

This clinical trial studies the following conditions: Atopic Dermatitis.

What interventions are being tested in trial NCT06947993?

The interventions under investigation include: Placebo (DRUG), GHZ339 (DRUG).

Who is sponsoring clinical trial NCT06947993?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06947993 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atopic Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atopic Dermatitis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.